



## CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS

Award ID:  
DP180040

Project Title:  
Clinical Evaluation of AVID100, a Highly Potent Antibody-Drug Conjugate,  
Focusing on Cancer Indications With High Unmet Medical Need

Award Mechanism:  
Texas Company Product Development Awards

Principal Investigator:  
Tikhomirov, Iliia

Entity:  
Formation Biologics Corporation

### Lay Summary:

Formation Biologics is developing an innovative pipeline of anti-cancer biotherapeutics called antibody-drug conjugates (ADCs). These next-generation treatments are designed to kill cancer cells while sparing healthy cells. Formation's lead ADC product, AVID100, has been extensively studied and has demonstrated excellent safety and efficacy. It efficiently kills cells from many deadly cancer types including breast, ovarian, head and neck, glioma, pancreatic, gastric and lung. AVID100 is now in early clinical trials in San Antonio exhibiting a good safety profile. Formation seeks CPRIT funding to expand testing of AVID100 in clinical trials allowing us to evaluate the anti-cancer activity of AVID100 in patients selected based on a test that predicts their likelihood of responding. It is expected that AVID100 will continue to exhibit superior efficacy relative to currently available drugs and could help address significant unmet cancer needs.

To achieve this goal, Formation will grow its operations in Austin, creating high-quality jobs and training staff in drug development and clinical trial operations. Formation is committed to the State of Texas and will ensure that funds are spent in Texas wherever possible. Cancer patients in Texas will have the potential to be among the first to benefit from treatment with AVID100.